Business ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials GLP-1 Drugs Weight Loss Drugs Acquisitions Obesity Drugs Oncology Eli Lilly Eli Lilly and Company Novo Nordisk Cancer Treatment

Bank of America Cuts Hims & Hers Target as GLP‑1 Pivot Squeezes Margins

Analysts now forecast weaker profits from the pivot to pricier branded GLP‑1 drugs.

Neurocrine to Acquire Soleno for $2.9 Billion in All-Cash Tender

EPO Signals Patent Grant for Silo Pharma’s PTSD Prevention Approach

Fosun Reports 2025 Results With RMB23.4 Billion in Write-Downs and a Higher 2026 Payout Target

Bristol Gate’s Q4 Letter Reaffirms Dividend-Growth Focus as Market Breadth Improves

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Sanofi Licenses Kali’s Tri-Specific Autoimmune Antibody KT501 in Deal Worth Up to $1.23 Billion

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

Roche Expands NVIDIA Partnership, Building Pharma’s Largest Hybrid‑Cloud AI Factory

Novo Nordisk Strikes Hims & Hers Deal for Ozempic and Wegovy, Drops Patent Suit

Eli Lilly’s Tirzepatide Surge Collides With Rich-Valuation Concerns

Hims & Hers Shares Ease After Rally Fueled by Novo Nordisk Deal and Analyst Upgrades

Eli Lilly to Invest $3 Billion in China to Build Orforglipron Manufacturing

GSK to Acquire 35Pharma for $950 Million to Add Pulmonary Hypertension Candidate HS235

Vistagen Investors Face March 16 Lead‑Plaintiff Deadline as Law Firms Seek Clients

Analysts Reinforce Eli Lilly’s Bull Case on Strong 2026 Guide, GLP-1 Momentum

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears